Market Insights Health Hospitals Inpatient Care

Treatment of Musculoskeletal Diseases - APAC

APAC

The Treatment of Musculoskeletal Diseases market in APAC is anticipated to witness a significant surge in revenue, with projections indicating that it will reach a staggering US$63.01bn by 2024.
Moreover, the market is expected to exhibit a steady growth rate of 3.98% annually from 2024 to 2028, resulting in a substantial market volume of US$73.66bn by the end of the forecast period.
In terms of global comparison, it is worth noting that United States is poised to generate the highest revenue in the Treatment of Musculoskeletal Diseases market, estimated at US$60,790.00m in 2024.
In Japan, there is a growing trend towards incorporating traditional Japanese medicine, such as acupuncture and moxibustion, in the treatment of musculoskeletal diseases.

Key regions: Europe, Canada, United States, Germany, India

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.